N/A
N=16
Clinical Investigation on the Blood Oxygenation at the Optic Nerve Head in Fabry Patients
Fabry Disease
Bottom Line
View on ClinicalTrials.gov: NCT02023086 ↗Enrolled (actual)
16
Serious AEs
0.0%
Results posted
Sep 2024
Primary outcome: Primary: Blood Oxygenation at the Optic Nerve Head — 60.8; 65.3 percentage of oxygen saturation
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- Contrast sensitivity measurement (Procedure); Slit Lamp assessment and intra-ocular pressure measurement (Procedure); Visual field testing (Procedure); Oxygen flow at the optic nerve head measurement (Procedure); Tropicamide (Drug); OSOME (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Université de Montréal
- Primary completion
- Sep 2016
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Blood Oxygenation at the Optic Nerve Head |
60.8; 65.3 | — |
| SECONDARY Field Defect |
98.4; 99.6 | — |
Summary
This study aimed to evaluate blood oxygenation at the optic nerve head in relation with visual field losses observed in many Fabry patients. Data collected allowed to evaluate if there is a link between these two entities.
Study lasted 2 years during which a limited number of Fabry patients had been compared to a control group to confirm any relationship between blood flow and field losses, and to see if these results varied over time.
HYPOTHESIS
1. Fabry patients will present significant differences in visual fields compared to control 2 There will be variability of the visual field defects on the long term but not on the short term 3 Blood oxygenation will be higher for Fabry patients 4 Blood volume at the optic nerve head will be the same for both groups.
Eligibility Criteria
Inclusion Criteria
Inclusion criteria (Fabry group):
- Aged over 18 years old
- Being diagnosed with Fabry disease
- 3 subjects will be under enzyme replacement treatment for the treatment of Fabry disease.
- 3 subjects will not receive enzyme replacement treatment
- Is fit to give legal consent.
- Is available for a period of 2 years
Inclusion criteria (CONTROL group):
- Matched for age and sex with group A - 6 participants
- Being healthy, with no known chronic systemic disease nor acute disease at the moment of the recruitment
- Is fit to give legal consent.
- Is available for a period of 2 years
Exclusion Criteria:( both groups):
- Presents with an active pathological ocular condition
- Presence of an abnormal optic nerve (congenital or acquired)
- Usage of topical ocular drug(s) at the time of selection
- To have known allergy to topical diagnostic drugs used in this study
- Usage of systemic medication with known effect on the visual field
Data sourced from ClinicalTrials.gov (NCT02023086). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.